Encompass More Asset Management Sells 300 Shares of Johnson & Johnson (NYSE:JNJ)

Encompass More Asset Management decreased its stake in Johnson & Johnson (NYSE:JNJ) by 12.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,156 shares of the company’s stock after selling 300 shares during the quarter. Encompass More Asset Management’s holdings in Johnson & Johnson were worth $312,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Dark Forest Capital Management LP bought a new position in Johnson & Johnson during the 2nd quarter worth approximately $223,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Johnson & Johnson by 1.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 390,025 shares of the company’s stock valued at $57,005,000 after buying an additional 4,046 shares during the period. Granite FO LLC purchased a new stake in Johnson & Johnson in the second quarter worth about $377,000. Sunbelt Securities Inc. boosted its position in Johnson & Johnson by 78.4% during the 2nd quarter. Sunbelt Securities Inc. now owns 56,956 shares of the company’s stock valued at $8,325,000 after acquiring an additional 25,032 shares in the last quarter. Finally, William B. Walkup & Associates Inc. bought a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $1,801,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Barclays dropped their price target on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 21st. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.06.

Johnson & Johnson Price Performance

Shares of JNJ opened at $152.91 on Tuesday. The firm has a market cap of $368.15 billion, a PE ratio of 22.99, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a fifty day simple moving average of $147.85 and a two-hundred day simple moving average of $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.